Cargando…
Clinicopathological significance and a potential drugtarget of RARβ in non-small-cell lung carcinoma: a meta-analysis and a systematic review
Lung cancer is the leading cause of cancer-related mortality in men worldwide. Aberrant RARβ promoter methylation has been frequently investigated in non-small-cell lung carcinoma (NSCLC), the most common form of lung cancer. The aim of present study was to carry out a meta-analysis and a systematic...
Autores principales: | Song, Xiaoyun, Shi, Kang, Zhou, Shi-Jie, Yu, Da-Ping, Liu, Zhidong, Han, Yi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4827914/ https://www.ncbi.nlm.nih.gov/pubmed/27103788 http://dx.doi.org/10.2147/DDDT.S96766 |
Ejemplares similares
-
The clinicopathological significance of hMLH1 hypermethylation in non-small-cell lung cancer: a meta-analysis and literature review
por: Han, Yi, et al.
Publicado: (2016) -
A Meta-Analysis of the Relationship Between RARβ Gene Promoter Methylation and Non-Small Cell Lung Cancer
por: Hua, Feng, et al.
Publicado: (2014) -
Recent advances in the design of RAR α and RAR β agonists as orally bioavailable drugs. A review
por: Borthwick, Alan D., et al.
Publicado: (2020) -
Clinicopathological significance and potential drug target of T-cadherin in NSCLC
por: Wang, Zhidong, et al.
Publicado: (2014) -
Is RARS-T a new disease entity or a subtype of RARS or ET?
por: Bang, Soo-Mee
Publicado: (2010)